Temozolomide treatment in glioma
Experiences in two university hospitals in finland

REFERENCES

• Steward LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011–8.
   PubMedGoogle Scholar
• Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 1994; 12: 2013–21.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Kros JM, Heimans JJ. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy. Neurology 1998; 51: 1140–5.
   PubMed Web of Science ®Google Scholar
• Paleologos N, Macdonald D, Vick NA, Cairncross JG. Neoadjuvant prokarbazine, CCNU and vincristine for ana-plastic and aggressive oligoendroglioma. Neurology 1999; 53: 1141–3.
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998; 90: 1473–9.
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner J. Chemotherapy for high-grade giomas. Br J Cancer 2000; 82: 1371–80.
   PubMed Web of Science ®Google Scholar
• Medical Research Council Brain Tumor Working Party. A randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrpcytoma: a Medical Research Council trial. J Clin Oncol 2001; 19: 509–18.
   PubMed Web of Science ®Google Scholar
• Reid JM, Stevens DC, Rubin J, et al. Pharmacokinetics of 3-methyl-(triazen-1-yl)imidazole-4-carboximide following admin-istration of temozolomide to patients with advanced cancer. Clin Cancer Res 1997; 3: 2393–8.
   PubMed Web of Science ®Google Scholar
• Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 523365) for refractory or relapsing malignancies. Br J Cancer 1999; 81: 1022–30.
   PubMed Web of Science ®Google Scholar
• Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multi-forme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375–82.
   PubMed Web of Science ®Google Scholar
• Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiformen at first relapse. Br J Cancer 2000; 83: 588–93.
   Google Scholar
• Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse: Temodal Brain Tumor Group. J Clin Oncol 1999; 17: 2762–71.
   Google Scholar
• Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003; 21: 646–51.
   PubMed Web of Science ®Google Scholar
• Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277–80.
   PubMed Web of Science ®Google Scholar
• Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [11C]methio-nine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000; 48: 43–52.
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumor response using [18F]-luorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 13: 1773–82.
   Google Scholar
• Harris MT, Rosenthal MA, Ashley DL, Cher L. An Autralian experience with temozolomide for the treatment of recurrent high grade glioma. J Clin Neurosci 2001; 8(4): 325–7.
   PubMedGoogle Scholar
• Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12(2): 259–66.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligoden-drogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001; 19(9): 2449–55.
   PubMedGoogle Scholar
• Osoba D, Brada M, Yung WKA, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000; 18: 1481–91.
   PubMed Web of Science ®Google Scholar
• Trent S, Kong A, Short SC, et al. Temozolomide as second-line chemotherapy for relapsed gliomas. J Neuro-Oncol 2002; 57(3): 247–51.
   PubMedGoogle Scholar
• Janinis J, Efstathiou E, Panopoulos C, et al. Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Med Oncol 2000; 17(2): 106–10.
   PubMedGoogle Scholar
• Dinnes J, Cave C, Huang S, et al. The effectiveness and cost-effectiveness of temozolmide for the treatment of recurrent malignant glioma: a rapid and systematic review Heath Tech Ass 2001; 5(13): 1–73.
   Google Scholar
• Lindholm L, Henriksson R, Rosen M, et al. Modified cost-effectiveness analysis takes into consideration: malignant glioma treatment more cost-effective than hip replacement. Läkartidningen 1999; 96(22): 2749–54.
   PubMedGoogle Scholar